Alkermes Inc

Type: Company
Name: Alkermes Inc
Nationality: United States
Web Address: http://www.alkermes.com/
Fact Sheet: Fact Sheet for Alkermes Inc
First reported Sep 16 2014 - Updated Sep 17 2014 - 1 reports

'Mad Money' Lightning Round: Buy, Buy, Buy St Jude Medical

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener. NEW YORK (TheStreet) -- Here's what Jim Cramer had to say about some of the stocks callers offered up during the Mad Money Lightning Round Monday ... [Published The Street Latest - Sep 16 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

Join Alkermes Contract Pharma Services at CpHI/ICSE meeting at booth 1D19

16-Sep-2014EuropeIn Hall 1 at booth 1D 19, Alkermes will be showcasing their expertise in fluid bed top spray granulation, fluid bed bead-coating, dry blend tablet coating and encapsulation as well as their experience in high potency manufacturing. Our ... [Published Manufacturing Chemist - Sep 16 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

Cramer: 'Intriguing situation' creates opportunity

On Monday's "Mad Money" Cramer looked at opportunities presented by Angie's List, JDS Uniphase. Also, what stock may be oversold due to Alibaba?Related Stocks:ALKERMES ANGIE'S LIST Apple Inc. FS INVESTMENT CORP HALCON RESOURCES CORP. JDS UNIPHASE ZYN ... [Published Stock Nod - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 16 2014 - 1 reports

Parkinson's biotech Civitas Therapeutics sets terms for $75 million IPO

Civitas Therapeutics, a biotech developing a therapy for re-emerging symptoms of Parkinson's disease, announced terms for its IPO on Monday. The Chelsea, MA-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14 ... [Published Renaissance Capital - Sep 15 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Techs can help Ireland compete on costs says team behind new hub

Ireland once was a drug making nexus,Making meds sold from Cairo to Texas.But with key patents gone,Firms are keen to move on,And a new Limerick tech hub reflects this, says director.The Irish Government announced plans to invest €5m ($6.4m) in an “industry-focused” ... [Published In-Pharmatechnologist - Sep 15 2014]
First reported Sep 09 2014 - Updated Sep 10 2014 - 4 reports

Alkermes (ALKS) Showing Resistance Near $43.48

After closing Tuesday at $42.67, Alkermes Inc (ALKS) presents an attractive opportunity to get a 7.18% return in just 73 days, which is an annualized return of 35.89% (for comparison purposes only). To enter this trade, sell one Nov. '14 $43.00 call for ... [Published MarketIntelligenceCenter.com - Sep 10 2014]
First reported Sep 08 2014 - Updated Sep 09 2014 - 5 reports

Alkermes patient enrollment complete in phase 2

Alkermes recently announced completion of patient enrollment in a phase 2 study of ALKS 3831, an investigational, novel, oral, broad-spectrum atypical antipsychotic medicine in development for the treatment of schizophrenia, according to a press release ... [Published Wilmington News Journal - Sep 09 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 7 reports

Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic

– Study to Evaluate ALKS 3831’s Efficacy, Safety and Tolerability in the Treatment of Schizophrenia and Attenuation of Olanzapine-Associated Weight Gain – – Topline Data From 12-Week, Double-Blind Treatment Period Expected in Early 2015 –DUBLIN, Ireland ... [Published PipelineReview - Sep 03 2014]
First reported Sep 02 2014 - Updated Sep 03 2014 - 5 reports

Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference

World News: 21:00 GMT Tuesday 2nd September 2014 . [ Alkermes plc via Businesswire via SPi World News ]This storyAlkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Morgan Stanley Global ... [Published SPi World News - Sep 02 2014]
First reported Aug 27 2014 - Updated Aug 28 2014 - 3 reports

Potential Alkermes (ALKS) Trade Targets 5.70% Return

MarketIntelligenceCenter.com's option-trade picking algorithms have identified an attractive covered-call trade on Alkermes Inc (ALKS). Look at the Oct. '14 $46.00 covered call for a net debit in the $43.52 area. This trade has a duration of 51 days. ... [Published MarketIntelligenceCenter.com - Aug 28 2014]
Entities: Alkermes Inc
First reported Aug 26 2014 - Updated Aug 26 2014 - 6 reports

Alkermes plc Announces Initiation Of Phase 1 Clinical Study Of ALKS 7106 For Treatment Of Pain

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of ALKS 7106, a proprietary, novel, oral, small-molecule drug candidate for the treatment of pain. The randomized, double-blind, placebo-controlled ... [Published BioSpace - Aug 26 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 9 reports

Regulatory Approval Sought for Long-Acting Schizophrenia Treatment Aripiprazole Lauroxil

Injectable agent is administered once a monthA new drug application (NDA) has been submitted to the FDA for approval of aripiprazole lauroxil (Alkermes PLC), an investigational, once-monthly, long-acting injectable atypical antipsychotic for the treatment ... [Published PT Community - Aug 25 2014]

Quotes

St Jude Medical : "This one has come down a lot and I want to buy it. I also like Edwards Lifesciences ."
He expalined that: "There was a real fear that unless our manufacturing industry could start competing on costs by becoming more innovative and knowledge-based work would start to go elsewhere ."
"Ireland has one of the best reputations globally in pharmaceutical manufacturing and it's important that we continue to support the sector so we attract further investment and retain existing investments. The PMTC provides compans with the opportunity to work together and harness academic expertise to address key manufacturing challenges they face. One specific re area is in process analytical technology which will help compans reduce cost and thus enhance competitiveness." Photos to follow from Provision 0876670082
After closing Thursday at $44.59, Alkermes Inc (http://www.marketintelligencecenter.com/symbol/ALKS "ALKS) presents an attractive opportunity to get a 6.66% return in just 71 days, which is an annualized return of 34.24% (for comparison purposes only). To enter this trade, sell one Nov. '14 $45.00 call for each 100 shares of ALKS for a net debit of about $42.19. The net debit for this trade is also the break even point, which means this position has 5.38% downside protection."

More Content

All (288) | News (97) | Reports (0) | Blogs (183) | Audio/Video (0) | Fact Sheets (1) | Press Releases (7)
sort by: Date | Relevance
Alkermes Plc COO Gordon G. Pugh Unloads 14,900 ... [Published American Banking News - Sep 20 2014]
Insider Selling: Alkermes Plc CEO Unloads 50,00... [Published American Banking News - Sep 20 2014]
Alkermes (ALKS) Showing Bullish Technicals With... [Published MarketIntelligenceCenter.com - Sep 19 2014]
Alkermes (ALKS) Trading Near $45.93 Resistance ... [Published MarketIntelligenceCenter.com - Sep 18 2014]
Alkermes (ALKS) Showing Bearish Technicals With... [Published MarketIntelligenceCenter.com - Sep 17 2014]
Worldwide Drug Delivery Technologies Market 201... [Published MyNewsDesk - Sep 17 2014]
Join Alkermes Contract Pharma Services at CpHI/... [Published Manufacturing Chemist - Sep 16 2014]
Alkermes (ALKS) Showing Bearish Technicals With... [Published MarketIntelligenceCenter.com - Sep 16 2014]
'Mad Money' Lightning Round: Buy, Buy, Buy St J... [Published The Street Latest - Sep 16 2014]
Cramer: 'Intriguing situation' creates opportunity [Published Stock Nod - Sep 16 2014]
Techs can help Ireland compete on costs says te... [Published In-Pharmatechnologist - Sep 15 2014]
Parkinson's biotech Civitas Therapeutics sets t... [Published Renaissance Capital - Sep 15 2014]
Alkermes (ALKS) Trading Near $43.74 Support Level [Published MarketIntelligenceCenter.com - Sep 15 2014]
Vectura Group Following A Familiar Path [Published Seeking Alpha - Sep 13 2014]
Otsuka Tries To Halt Alkermes Ride On Abilify’s... [Published BioPortfolio - Sep 13 2014]
Minister English launches ¤5m Pharmaceutical Ma... [Published Noodls - Sep 12 2014]
Potential Alkermes (ALKS) Trade Targets 6.66% R... [Published Individual.com - Sep 12 2014]
€5m Pharmaceutical Manufacturing Technology Cen... [Published Business & Leadership - Sep 12 2014]
Minister English launches €5m Pharmaceutical Ma... [Published Business & Finance - Sep 12 2014]
Potential Alkermes (ALKS) Trade Targets 6.66% R... [Published MarketIntelligenceCenter.com - Sep 12 2014]
Govt launch E5m pharma research centre [Published Ireland Business World - Sep 12 2014]
Opioids, Cannabis, Scientists and Money, Lots [Published Media Awareness Project - Sep 12 2014]
Higher Authorities? - Pharmaceutical Companies,... [Published Health Care Renewal - Sep 11 2014]
Alkermes (ALKS) Showing Bearish Technicals With... [Published MarketIntelligenceCenter.com - Sep 11 2014]
Alkermes' Corporate Presentation to be Webcast ... [Published 4 Traders - Sep 11 2014]
Alkermes Announces Completion of Patient Enroll... [Published 4 Traders - Sep 11 2014]
Patent Issued for Compositions of Buprenorphine... [Published 4 Traders - Sep 11 2014]
Weekly FDA Enforcement Report For Drugs 9/3/14 [Published Pharmaceutical Online - Sep 11 2014]
Alkermes (ALKS) Showing Resistance Near $43.48 [Published MarketIntelligenceCenter.com - Sep 10 2014]
Alkermes Reports Phase 2 Study of ALKS 3831 [Published HighBeam Research - Sep 09 2014]
1 2 3 4 5 6 7 8 9 10
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Alkermes (ALKS) Showing Bullish Technicals With... [Published MarketIntelligenceCenter.com - Sep 19 2014]
Option-trade picking algorithms patented by MarketIntelligenceCenter.com found a trading opportunity with Alkermes Inc (ALKS) that should provide a 7.80% return in just 64 days. Sell one Nov. '14 call at the $47.00 level for each 100 shares of Alkermes ...
Alkermes (ALKS) Trading Near $45.93 Resistance ... [Published MarketIntelligenceCenter.com - Sep 18 2014]
MarketIntelligenceCenter.com's option-trade picking algorithms have identified an attractive covered-call trade on Alkermes Inc (ALKS). Look at the Nov. '14 $46.00 covered call for a net debit in the $42.93 area. This trade has a duration of 65 days. ...
Alkermes (ALKS) Showing Bearish Technicals With... [Published MarketIntelligenceCenter.com - Sep 17 2014]
After Tuesday’s trading in Alkermes Inc (ALKS) the option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center uncovered a trade that offers a 6.76% return, or 37.39% annualized (for comparison purposes only), ...
Alkermes (ALKS) Showing Bearish Technicals With... [Published MarketIntelligenceCenter.com - Sep 16 2014]
The patented option trade-picking algorithms behind MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered call trade on Alkermes Inc (ALKS) that includes 6.64% downside protection. Sell one contract of the Nov. '14 $44.00 ...
Alkermes (ALKS) Trading Near $43.74 Support Level [Published MarketIntelligenceCenter.com - Sep 15 2014]
For a hedged play on Alkermes Inc (ALKS), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Nov. '14 $45.00 covered call for a net debit in the $41.70 area. That is also the break-even stock price for the covered call. This ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Technical Summary on Biotech Equities -- Alkerm... [Published Financial Services - Aug 18 2014]
Clinical Trial Data, NDA Submissions, and Board... [Published Financial Services - Jun 25 2014]
Biotech Equities Under Review -- Research on Ac... [Published Financial Services - May 09 2014]
Priority Reviews, Preliminary Earnings Releases... [Published Financial Services - Apr 11 2014]
Certifications, Authorizations, Stock Updates, ... [Published Financial Services - Apr 10 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.